Loading...
Market
What will be the outcome of AbbVie's first clinical trial involving ALIA-1758 by end of 2026?
2
Resolution / Starting Odds
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
ClinicalTrials.gov or peer-reviewed publications
Story
AbbVie Acquires Privately Held Aliada Therapeutics for $1.4 Billion, Boosting Alzheimer's Focus with ALIA-1758
Oct 28, 2024, 12:11 PM
AbbVie Inc. has announced the acquisition of privately held Aliada Therapeutics for $1.4 billion in cash. This strategic move aims to bolster AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. The acquisition includes Aliada's lead compound, ALIA-1758, and novel blood-brain barrier technology. The deal represents a significant return on investment for venture capital, with an initial investment of $33 million yielding $1.4 billion.
View original story
Similar markets
Q4 2024 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%
Yes • 50%
No • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%